We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

By LabMedica International staff writers
Posted on 18 Jul 2024

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. More...

However, routine blood testing remains limited worldwide. Many adults avoid routine blood tests due to their complexity and the long wait times for results, which can lead to delayed interventions or missed diagnoses, resulting in substantial avoidable costs. Now, a groundbreaking diagnostic platform is set to transform the existing global infrastructure by providing lab-accurate, actionable test results that aid in the early detection and prevention of chronic conditions.

Truvian Health (San Diego, CA, USA) has developed an automated benchtop system that allows simple, accurate, and comprehensive routine blood tests to be conducted directly in clinics, doctor’s offices, and pharmacies. Utilizing patented technologies and intelligent integration, Truvian’s compact device offers a convenient and economical alternative to traditional off-site labs, delivering quick, lab-accurate results from just a small blood sample, and enhancing healthcare decision-making. The Truvian system combines clinical chemistry, immunoassay, and hematology tests in one operation and can simultaneously handle multiple types of assays. Its initial offering, a comprehensive wellness panel, covers over 90% of the most commonly requested routine blood tests, requiring only one tube and 8 drops of blood.

Truvian has shared data from various independent clinical studies showing that its system's results match those from central laboratories across an extensive range of tests. The platform has been tested with over 50,000 samples from approximately 5,000 donors to date, achieving a reliability rate of over 98%. This system’s capability to provide central lab-quality results in any setting could fundamentally change the way chronic diseases are detected and managed. Immediate access to results enables healthcare providers to diagnose and treat patients without delay, enhancing patient involvement in their health decisions and improving outcomes. By consolidating blood diagnostics into a single visit, the platform reduces healthcare costs for both patients and systems, simplifies the monitoring and management of chronic conditions, and promotes healthier, longer lives. Truvian is now working towards securing US Food and Drug Administration (FDA) clearance for its blood testing platform.

“We are on the cusp of delivering what the world needs to counter today’s non-communicable disease burden and unsustainable healthcare costs,” said Jay Srinivasan, chief executive officer of Truvian.

Related Links:
Truvian Health


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.